



# HHS Public Access

Author manuscript

*Nat Rev Rheumatol.* Author manuscript; available in PMC 2016 January 01.

Published in final edited form as:

*Nat Rev Rheumatol.* 2015 January ; 11(1): 21–34. doi:10.1038/nrrheum.2014.157.

## Repair and tissue engineering techniques for articular cartilage

**Eleftherios A. Makris, Andreas H. Gomoll, Konstantinos N. Malizos, Jerry C. Hu, and Kyriacos A. Athanasiou**

Department of Biomedical Engineering (E.A.M., J.C.H.), University of California Davis, One Shields Avenue, Davis, CA 95616, USA. Department of Orthopaedic Surgery (K.A.A.), University of California Davis, One Shields Avenue, Davis, CA 95616, USA. Department of Orthopaedic Surgery and Musculoskeletal Trauma, University of Thessaly, Biopolis, Larisa, 41110, Greece (K.N.M.). Department of Orthopaedic Surgery, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, 02115, USA (A.H.G.)

### Abstract

Chondral and osteochondral lesions due to injury or other pathology commonly result in the development of osteoarthritis, eventually leading to progressive total joint destruction. Although current progress suggests that biologic agents can delay the advancement of deterioration, such drugs are incapable of promoting tissue restoration. The limited ability of articular cartilage to regenerate renders joint arthroplasty an unavoidable surgical intervention. This Review describes current, widely used clinical repair techniques for resurfacing articular cartilage defects; short-term and long-term clinical outcomes of these techniques are discussed. Also reviewed is a developmental pipeline of regenerative biological products that over the next decade could revolutionize joint care by functionally healing articular cartilage. These products include cell-based and cell-free materials such as autologous and allogeneic cell-based approaches and multipotent and pluripotent stem-cell-based techniques. Central to these efforts is the prominent role that tissue engineering has in translating biological technology into clinical products; therefore, concomitant regulatory processes are also discussed.

### Introduction

The management of articular cartilage defects is one of the most challenging clinical problems for orthopaedic surgeons. Articular cartilage, a highly organized tissue with

---

Correspondence to: K.A.A. athanasiou@ucdavis.edu.

Competing interests

A.H.G. declares that he consults for SANOFI S.A. The other authors declare no competing interests.

Review criteria

We searched for original articles focusing on cartilage repair and regeneration in MEDLINE, PubMed, Embase and the Cochrane Controlled Trials Register, published 2000–2014. The search terms alone and in combination were “cartilage repair”, “cartilage regeneration”, “cartilage randomized controlled trials”, “cartilage cohorts”, “cartilage systematic reviews”, “cartilage scaffolds”, “engineered cartilage”, “chondrocyte tissue engineering”, “stem cells and chondrocyte” and “chondrocyte and growth factors”. Preliminary searches were undertaken in March 2014 and were updated in May 2014. All publications identified were English-language, full-text papers. We also searched the reference lists of identified articles for additional publications.

Author contributions

All authors contributed equally to researching data for the article, substantially contributing to discussion of content, writing and review/editing of the manuscript before submission.

substantial durability, has a limited intrinsic healing capacity. Damage from trauma or degenerative pathology frequently results in gradual tissue deterioration, leading to debilitating joint pain, functional impairment and degenerative arthritis.<sup>1</sup> Currently, the standard surgical intervention for end-stage degenerative joint pathology is total joint replacement. Early surgical intervention for symptomatic cartilage lesions, including osteotomy and autologous osteochondral graft transplantation, has been suggested to restore normal joint congruity and minimize further joint deterioration.<sup>2</sup> Often, these techniques are not long-term clinical solutions, prompting the development of regenerative medicine and tissue engineering approaches to restore articular cartilage. Strategies include cell-based (with or without scaffolds) or whole-tissue transplantation techniques.

In this Review, we discuss the basic science, indications, advantages, shortcomings and outcomes of interventions for cartilage healing. The goal is to provide an evidence-based assessment for the treatment of articular cartilage pathology by reviewing the literature, with particular focus on the clinical outcomes of prospective randomized controlled trials (Table 1). Moreover, we discuss current prospective tissue engineering trials for cartilage repair, with an emphasis on cell sources, the clinical aspects of cell administration, the use of mesenchymal stem cells (MSCs), growth-factor-based therapies and cell-free, implantation-based therapies. Finally, the scientific and regulatory challenges in translating these approaches to clinical practice are discussed.

## Present repair techniques

### Microfracture

Microfracture was introduced to the clinic after other bone-marrow-stimulation techniques were used in the late 1980s and early 1990s to penetrate subchondral bone. This technique enhances migration of MSCs from bone marrow to the site of a cartilage defect (Figure 1); however, microfracture often results in the formation of fibrocartilage that is biochemically and biomechanically inferior to hyaline articular cartilage.<sup>3,4</sup> A case series study has shown that without the mechanical robustness of hyaline tissue, the repair tissue is vulnerable to mechanical joint forces and typically deteriorates ~18–24 months after surgery, as shown by the modified Cincinnati Rating System for knee and International Cartilage Repair Society (ICRS) scores postoperatively, compared with baseline scores (Box 1).<sup>4</sup> Such deterioration is particularly evident when treating large defects or those located in the patellofemoral joint.<sup>4</sup> Furthermore, owing to the penetration of the subchondral bone, intralesional osteophytes develop in 20–50% of cases.<sup>5</sup> The altered biomechanics of the sclerotic bone might be the cause of a threefold-to-sevenfold increase in the failure rate of autologous chondrocyte implantation (ACI) when performed after prior microfracture.<sup>6,7</sup> Specific indications have, therefore, been proposed for performing this technique in cartilage lesions. These indications are based on the size, depth and location of the lesion in the joint, as well as the patient's age and BMI (Figure 2). Although the FDA and many clinicians still consider microfracture to be the gold standard for cartilage repair, prospective comparative studies show that microfracture might delay cartilage degeneration only in the short-term; more than 5 years after surgery, treatment failure can be expected regardless of the size of the lesion.<sup>8,9</sup> A detailed description of the indications, clinical application, rehabilitation and

outcomes of the standard microfracture procedure has been reviewed elsewhere,<sup>10</sup> and is outside the scope of this article. However, a brief understanding of this technique is important, as microfracture has become a ubiquitous approach to surgical regeneration of cartilage, the shortcomings of which have ultimately spurred the development of procedures that aim to fully regenerate articular cartilage.

### Autologous chondrocyte implantation

The inconsistent outcomes of microfracture prompted the development of ACI. To perform this technique, a full-thickness sample from a low-weight-bearing region of the joint is collected by biopsy punch during a first arthroscopic operation to provide a chondrocyte population that is then expanded *in vitro*, yielding ~12–48 million cells. During a second operation the chondrocytes are implanted into the debrided cartilage defect and covered by a membrane. This technique has two major benefits: using a patient's own cells avoids potential immune complications or viral infections from transplanting allogeneic cells or foreign materials; and as opposed to autologous osteochondral implantation, the small biopsy minimizes complications for the chondrocyte donor.<sup>11,12</sup>

Positive clinical and functional outcomes of ACI have been confirmed by clinical trials.<sup>13, 14, 15</sup> Long-term case series with >10 years follow-up have demonstrated that ACI is an effective and durable treatment for large (>4 cm<sup>2</sup>) knee cartilage lesions.<sup>13,14</sup> Other clinical trials have reported similar results,<sup>16,17</sup> highlighting the benefits of combining ACI with a corrective osteotomy.<sup>18</sup> Whether ACI is superior to other standard treatments in prospective randomized controlled clinical trials, however, is controversial. A study comparing ACI to autologous osteochondral transplantation (mosaicplasty) found ACI to have superior clinical results 10 years postoperatively;<sup>19</sup> other studies demonstrated superior outcomes for ACI when compared with microfracture for the treatment of cartilage defects >3 cm<sup>2</sup> in size.<sup>20,21</sup> Studies of ACI and microfracture for smaller defects, however, have found similar clinical and radiographically evident outcomes,<sup>22</sup> although ACI has been associated with improved structural repair.<sup>12,23</sup> Additional large-scale prospective randomized studies with a long-term follow-up are necessary to identify and understand the clinical criteria, indications and contraindications for when ACI might provide superior clinical outcomes over less invasive and costly techniques, such as microfracture. Ideally, functional evaluation should be supplemented by characterization of neotissue with sophisticated imaging or arthroscopic techniques.

ACI has three major drawbacks: two operations are needed; a long recovery time (6–12 months) is required to ensure neotissue maturation and achieve improved clinical scores from baseline; and ACI is a multistage, complex procedure. The most frequently reported adverse event after ACI, using a periosteal flap to seal the implanted cells in the cartilage defect, is hypertrophy of the flap.<sup>24</sup> Therefore, alternative approaches utilize artificial matrices such as porcine membranes consisting of mixtures of collagen types I and III or hyaluronic acid scaffolds.<sup>25–27</sup> However, these materials increase the likelihood of an immune reaction to the allogeneic scaffold, and their use is currently considered off-label in the USA. Preliminary studies have also shown that autologous chondrocytes 'dedifferentiate' into fibrochondrocytes in culture.<sup>28</sup> However, other work shows they can

redifferentiate and express chondrocytic markers after being reintroduced into a 3D *in vitro* culture system.<sup>29</sup> To standardize clinical outcomes of ACI, patient-specific and cartilage defect-specific factors have been established to generate a treatment algorithm that improves the likelihood of a successful outcome (Figure 2). Nevertheless, large-scale cohort studies are needed to further investigate the cost-effectiveness of ACI.

Overall, ACI has proven beneficial for treating cartilage defects, but more research needs to be done to develop biomechanically stable matrices, to achieve faster maturation of the neotissue and better integration with the host tissue. Furthermore, work is required to standardize and optimize the technique and the post-surgery functional evaluation so that surgeon and patient biases do not affect the functional outcome.

### Scaffold-based techniques

The lack of a supportive scaffold material to guide matrix synthesis and organization might, in part, account for the outcome variability across patient populations treated with chondrocyte implantation techniques. *Ex vivo* studies have shown that successful cartilage regeneration is dependent both on the chondrocyte proliferation rate and on the differentiation capacity of stem cells within a tissue-engineered 3D matrix, a structure that acts as a cell carrier to maintain and support the crucial characteristics of the tissue.<sup>30</sup> The second generation of ACI has therefore focused on the development of scaffold-based approaches for delivering chondrocytes to the cartilage defect site. Scaffold-based approaches have major advantages to scaffold-free techniques: these advantages include, increased control to better fill the cartilage defect; fewer donor site complications; a less technically challenging procedure; and shorter postoperative recovery time due to increased graft stability. Additionally, because the chondrocytes are cultured in a 3D environment, they are less prone to dedifferentiation and therefore produce a more hyaline-like cartilage.<sup>31</sup> Furthermore, *in vitro* culture prior to implantation might help to maintain quality control of scaffold-based repair.

**MACI**—Matrix-induced autologous chondrocyte implantation (MACI) is the most common scaffold-plus-cell-based cartilage repair technique currently in clinical practice. Similar to ACI, MACI requires two surgical procedures. The first surgery collects autologous tissue from which the patient's chondrocytes are isolated. Once isolated, the cell population is expanded *in vitro* and then seeded for 3 days on an absorbable porcine-derived mixed collagen (type I and III) membrane prior to implantation. These membranes are specifically engineered to promote chondrocyte infiltration on one side and lubrication on the other. To implant the cell-seeded scaffold a mini-arthrotomy exposes and debrides the lesion, after which the matrix is implanted and secured using fibrin glue, with the cell-laden side facing the subchondral bone and the low-friction surface facing the joint cavity (Figure 1).

Although case series of MACI have had promising clinical and histological results,<sup>32,33</sup> the superiority of MACI over existing techniques remains unproven. One of the few prospective randomized clinical trials to assess MACI found comparable clinical, arthroscopic and histological outcomes between MACI-treated or ACI-treated patients;<sup>34</sup> however, the MACI-treated group had a lower rate of hypertrophy of the graft. Another study reported no

differences in International Knee Documentation Committee (IKDC) scores, Tegner activity scores or the Short Form-36 from patients 24 months after undergoing either MACI or ACI; however, Lysholm and Guillquist knee functionality scores showed better efficacy of the ACI technique than MACI (Box 1).<sup>35</sup> A separate study found outcomes to be better with MACI than microfracture for patients with large (>4 cm<sup>2</sup>) defects 2 years after surgery.<sup>20</sup> Overall, these studies found MACI to have similar, if not superior, functional outcomes to either ACI or microfracture in a follow-up study after 2 years. Although MACI is technically attractive in terms of reproducibility, safety, surgical simplicity and reducing invasiveness and intraoperative time, the expense of the technique warrants further investigation. Large prospective randomized trials with long follow-up periods are also necessary to identify clinical criteria, indications and contraindications to optimize the performance of this technique.

**Hyaluronan-based scaffolds**—Hyaluronan-based scaffolds are another means of implanting chondrocytes within a 3D biodegradable environment. Similar to collagen-derived matrices, the hyaluronic-acid-based scaffold is intended to promote and maintain the chondrocytic phenotype and collagen type II synthesis during *in vitro* culture, as well as after implantation (Figure 1).<sup>36</sup> Although, *ex vivo* studies have reported that the degradation rate of these materials can be tailored to match the rate of the synthesis of extracellular matrix (ECM) by the cells to aid in integration with the defect site,<sup>36,37</sup> this finding has not been confirmed in long-term follow-up clinical studies.

However, treating cartilage defects with autologous chondrocytes delivered with a hyaluronic-acid-based scaffold has shown promise. In case series, hyaline-like cartilage has been shown to develop ~1 year after implantation,<sup>27,38</sup> and improved functional and health-related quality of life outcomes have been reported 3 years after implantation, compared with baseline.<sup>27</sup> A prospective cohort study, evaluating athletes treated with either hyaluronic-acid-based MACI or microfracture, found comparable outcomes in ICRS, IKDC and Tegner scores (Box 1) between the two groups 2 years postoperatively.<sup>38</sup> However, better IKDC scores were detected 7.5 years after operation in the hyaluronic-acid-based MACI group than in the group treated with microfracture. Interestingly, athletes treated by microfracture required at least 8 months of recovery before returning to the field, whereas those receiving hyaluronic-acid-based MACI required 12.5 months.<sup>38</sup> Thus, although hyaluronic-acid-based MACI ultimately has better clinical outcomes than microfracture, longer rehabilitation is required. In a small cohort study, statistically significant differences were not found in the functional outcomes or the histological and immunohistochemical composition of hyaluronic-acid-based and fibrin-based scaffolds (both seeded with chondrocytes) 1 year after implantation.<sup>39</sup> Although scaffold-based ACI for cartilage regeneration is approved in Europe, and FDA approval is currently pending in the USA, well-designed comparative studies with long follow-up periods are needed to confirm the potential therapeutic and economic benefits.

## Future regenerative approaches

### *Ex vivo* chondrocyte-seeded scaffolds

Despite the technical advantages of MACI, clinical studies have revealed the functional outcomes to be similar to those of ACI.<sup>34,35</sup> A plausible explanation is that after chondrocyte seeding, the collagen matrices are implanted into the patient within 3 days, leaving the MACI neotissue implant immature and therefore vulnerable. To improve the efficacy of such tissue engineering procedures, novel approaches are in development (Figure 3) to introduce autologous chondrocytes into a 3D matrix and culture them *in vitro* for longer periods, typically 4–6 weeks. During this time, articular chondrocytes produce their own ECM components within the 3D environment, resulting in an implant with biochemical integrity similar to healthy articular cartilage. Surgical techniques similar to those established for MACI are used to engineer and implant the tissue. The enhanced mechanical robustness of the neotissue after long-term *ex vivo* 3D culture makes implants structurally and functionally more mature than MACI-based implants and, thus, potentially able to withstand normal joint loads earlier post-implantation. This robust neotissue might improve short-term and long-term functional outcomes for patients, and *ex vivo* and preclinical outcomes are promising,<sup>40–42</sup> although comparative clinical studies are needed to confirm this hypothesis. Also imperative is to investigate methods to form a stable interface between the implant and host tissue environment; a low integration potential raises the failure rate of the technique.<sup>43</sup>

Although *in vitro* culture of autologous chondrocyte-seeded 3D matrices might result in robust chondral implants, time alone is not enough to promote sufficient maturation of the engineered tissue. Researchers have therefore sought exogenous chondrocyte stimuli analogous to those that promote biomechanically robust implants *in vivo*. Walking, for example, can create loads of ~4–5 times body weight on normal human knee cartilage.<sup>44</sup> Chondrocytes respond to high mechanical loads by proliferating and producing ECM.<sup>45</sup> Thus, exogenous mechanical stimulation has been applied to cell-laden matrices *in vitro*, in the form of either hydrostatic pressure<sup>40</sup> or dynamic compression,<sup>41</sup> to improve matrix maturation and the function of neotissues. Research has also identified growth factors that help chondrocytes to maintain their phenotype and ability to produce ECM. The most important growth factors widely used in cartilage regeneration and tissue engineering *ex vivo* studies are transforming growth factor  $\beta$  (TGF- $\beta$ ) family members, particularly TGF- $\beta$ 1 and TGF- $\beta$ 3.<sup>46</sup> *In vitro* tissue engineering studies have confirmed that TGF- $\beta$  stimulation helps maintain the native chondrocyte phenotype, enhances the biochemical composition and functional properties of the neotissue, and promotes the development of implants that exhibit structure–function relationships similar to native articular cartilage.<sup>40,41,47</sup> Despite extensive research in this field, there is no general consensus regarding the optimal type, level and application time of growth factor and mechanical stimulation, or for combinations of these factors, to develop robust hyaline-like tissues. The array of treatment possibilities complicates and thereby increases the cost of research in this field.

Only a few human clinical reports on the outcomes of autologous chondrocyte-laden, engineered scaffold-based approaches to cartilage regeneration are available. In an FDA



phase I clinical trial, eight patients were implanted with tissue-engineered, autologous-chondrocyte-seeded, collagen type I scaffolds, which were subjected to hydrostatic pressure prior to surgery.<sup>48</sup> After 1 year, cartilage defects in seven of eight patients had almost completely filled with a mature, organized repair-tissue. These promising results led to a phase II clinical trial, which found that the technique had a similar safety profile as microfracture and had better clinical outcomes in most functional scores 2 years after implantation.<sup>49</sup> Although immune reactions to the collagen scaffold were not found in this study, long-term studies should evaluate this potential.

### Alternative cell and tissue sources

Current cell-based clinical practices for treating articular cartilage defects and degeneration only utilize autologous chondrocytes. Despite efforts to recapitulate the *in vivo* environment with 3D culture, bioreactors, and exogenous mechanical and biochemical stimulation, a repair tissue with native hyaline cartilage properties has yet to be produced. Thus, in an effort to avoid some of the drawbacks associated with autologous chondrocyte therapy, methods have developed using stem cells, many of which are currently in a queue for FDA approval for clinical studies.

**Bone marrow MSCs**—Of the various types of stem cell in the body, MSCs derived from bone marrow have many advantages for clinical use. They are comparatively easy to isolate and proliferate, allowing for the potential to obtain them from donors and to store them in readily available cell banks. Furthermore, extensive preclinical work *in vitro* and *in vivo* confirmed by clinical trials has found that human bone marrow MSCs are capable of differentiating into both cartilage<sup>50–53</sup> and bone,<sup>54</sup> meriting their use for regeneration of both osteochondral and chondral defects. Specifically, bone marrow MSCs derived from patients with advanced osteoarthritis were shown *ex vivo* to produce proteoglycan and collagen type II and to maintain a chondrocytic phenotype in a scaffold in the presence of TGF- $\beta$ 1.<sup>55,56</sup> Another beneficial trait is their ability to selectively migrate to diseased tissues and organs, where they have been found to secrete T-cell-suppressive cytokines<sup>57,58</sup> known to be important for allotransplantation and xenotransplantation.<sup>59</sup> In the case of cartilage repair, bone marrow MSCs might enable a targeted repair system that promotes trophic effects through the release of synthetic, proliferative and regenerative factors directly into chondral lesions.<sup>60</sup> By creating a regenerative environment with the release of chemotactic factors,<sup>61</sup> bone marrow MSCs might also drive endogenous stem cells to enter the cartilage defect and aid in the regeneration of damaged tissue.

Preliminary human clinical studies have investigated the cartilage regenerative potential of injected human bone marrow MSCs (Figure 3). In a case series, four patients with osteoarthritis were treated each with a single injection of bone marrow MSCs into the knee, 1 year after which the patients had decreased pain and improved joint mobility without any adverse effects.<sup>62</sup> Good clinical and functional results were also reported in a similar case series at a 6-month follow-up.<sup>63–65</sup> Despite the potential application of bone marrow MSCs, much remains to be investigated: such as, the number of cells required to promote cartilage regeneration; whether one or more injections are required to reach the desired effect; the optimal time-window for these injections; and the long-term safety of the technique. Finally,

prospective controlled studies with long-term follow-up are needed to investigate the therapeutic potential of bone marrow MSC injection versus established cartilage repair techniques.

ACI-like and MACI-like strategies can use bone marrow MSCs in conjunction with scaffolds, as opposed to autologous chondrocytes (Figure 3). Many clinical case series have used cultured bone marrow MSCs seeded into collagen scaffolds for the treatment of symptomatic cartilage defects.<sup>52,66,67</sup> Most of these studies, which have been with a small number of patients, have reported good results less than 1 year after implantation. In a large-scale observational cohort study, 72 patients with cartilaginous lesions were treated with either ACI or bone marrow MSC implantation covered with a periosteal patch.<sup>53</sup> The stem cells were found to treat the chondral defects as effectively as ACI in terms of 2-year postoperative clinical and functional outcomes. More importantly, the bone marrow MSC treatment was less expensive than ACI, avoided the risk of donor site morbidity and did not require an additional operation to obtain the cells. However, pain from the surgical site from which bone marrow MSCs were harvested, along with other potential adverse effects of the additional surgical intervention, are concerns meriting further investigation.

Overall, the positive outcomes of these studies accentuate the potential of bone marrow MSC therapy for cartilage repair. However, it remains to be seen how these techniques compare with more established procedures in comparative clinical studies, and further research is necessary to understand the feasibility of their clinical application. The potential benefit of preimplantation differentiation of bone marrow MSCs with growth factors or other biophysical or biomechanical stimuli that promote phenotypic change and stability also warrants additional investigation. As MSCs are multipotent, studies to confirm the safety of transplanting them are also needed. Finally, future studies should directly compare bone marrow MSCs with other stem cells for their ability to regenerate cartilage.

**Other MSC sources**—Most cartilage regeneration work using MSCs has been with bone-marrow-derived cells. Bone marrow aspiration, although painful, is an established method. However, stem cells can be derived from other sources, including adipose tissue, muscle, corticocancellous bone, synovium, periosteum and umbilical cord.<sup>68</sup> Human adipose-derived stem cells are the most readily accessible, and *in vitro* studies have shown these cells to have a similar proliferative profile and differentiation capacity to bone marrow MSCs.<sup>69,70</sup> Adipose-derived stem cells have been regarded as an ‘ideal’ cell source due to our ability to isolate them in comparatively large quantities, their nonimmunogenic and anti-inflammatory properties,<sup>71</sup> minimal ethical considerations associated with their use and, compared with stem cells from other sources, their capacity for proliferation and differentiation is less likely to be affected by a person’s age.<sup>72</sup> The clinical feasibility and safety of human adipose-derived MSCs to treat degenerative cartilage pathology was investigated in a case series by injecting the cells into the osteoarthritic knee joint of elderly patients (mean age 70.3 years, range 65–80 years) in combination with arthroscopic lavage.<sup>73</sup> The treatment resulted in improved physical function, cartilage healing and pain reduction; however, this technique has some of the same problems as bone marrow MSC joint injections: these problems include the number of cells required to promote cartilage regeneration; whether one or more injections are required to reach the desired effect; the



optimal time-window for these injections; and the long-term safety of the technique. In addition, quantitative evidence of improvement, for example with biopsy or MRI, is needed.

The chondrogenic potential of stem cells from other sources has also been studied; autologous peripheral blood stem cells (PBSCs) have been the most clinically investigated, albeit primarily in case series.<sup>74–76</sup> A randomized trial investigated articular cartilage regeneration in patients aged 18–50 years with knee chondral lesions (ICRS grade 3 and grade 4 lesions) treated with arthroscopic subchondral drilling followed by postoperative intra-articular injections of hyaluronic acid, with or without PBSCs. The study found the PBSC group had improved quality of cartilage as shown in the ICRS visual assessment scale histology score and an MRI-based morphological score over those of the control group 18 months after injection.<sup>77</sup> *In vitro*, synovial-derived stem cells have a better chondrogenic potential than stem cells from other sources,<sup>78,79</sup> as shown by the development of hyaline-like neotissue when they are seeded onto scaffolds,<sup>80</sup> although clinical studies using these cells have not yet been conducted. Multilineage dermal stem cells have also been isolated and have a high capacity for *in vitro* chondroinduction in a cartilage tissue engineering study.<sup>81</sup> Much *in vitro* work remains to be done to understand the chondrogenic potential of stem cells and to optimize chondrocyte differentiation. Future preclinical and comparative clinical studies will hopefully answer the many questions concerning the benefits, clinical applicability and cost-effectiveness of these cells, and they might identify indications and criteria for their use in cartilage healing.

**Induced pluripotent stem cells**—Induced pluripotent stem cells (iPSCs) also show promise for chondrogenic application in the clinic. These cells have the ability to differentiate *in vitro* into either cartilage<sup>51,82</sup> or bone.<sup>83,84</sup> The expression of chondrogenic markers in human iPSCs was shown to be either comparable or superior to bone marrow MSCs,<sup>51</sup> whereas the quality of cartilage repair tissue formed by either human iPSC pellets or a human iPSC–alginate hydrogel in a rat osteochondral defect model was substantially better than the tissue formed in empty defects or defects filled with alginate hydrogel.<sup>51,82</sup> In an *in vitro* study, iPSCs derived from reprogrammed human synovial cells of patients with advanced osteoarthritis were used to generate mesenchymal lineage cells, such as chondrocytes and osteoblasts.<sup>84</sup> Despite these promising results, several questions remain to be answered: these questions pertain to the chondrogenic efficacy of these cells; optimal practices for isolating, differentiating and purifying them *ex vivo*; the undesired genomic modifications associated with most reprogramming protocols, and the potential of teratogenesis or other *in vivo* tissue malformations; and validation of iPSC-based therapies by the FDA and the European Medicines Agency. Although much remains to be understood, the enormous potential of iPSCs for treating cartilage degeneration merits future studies to address these uncertainties.

### Fresh and particulated allografts

Aside from cell-based methods, fresh osteochondral allografts, as well as particulated cartilage allografts, have been used to fill cartilage defects and promote regeneration (Figure 3). An advantage of using allograft tissues is that they are not regulated by the FDA, and thus bypass costly and time-consuming clinical trials. Fresh osteochondral allograft

transplantation has had positive clinical benefits for young, active individuals. Clinical results have found that these grafts last 1–25 years, depending on graft chondrocyte viability and mechanical stability of the host–graft interface; when such criteria were met, histological evaluation consistently detected hyaline repair tissue.<sup>85</sup>

Particulated cartilage allografts, on the other hand, are the focus of fewer scientific publications. These grafts are formed by combining particulated cartilage with a fibrin glue to form a construct that is then placed into the cartilage defect. Limited autodigestion of the ECM releases superficial chondrocytes, which produce additional ECM that integrate the cartilage particles, filling the defect. Clinical experience with this technique is limited to short-term (2-year follow-up) studies, most of which are case reports and case series demonstrating feasibility, safety and efficacy, with improvements in subjective patient clinical scores and MRI evidence of good defect filling.<sup>86,87</sup> An alternative approach to introducing autologous cartilage fragments into the cartilage defect utilizes a scaffold-based technique. Specifically, in a single surgery, hyaline cartilage is arthroscopically harvested from a low load-bearing region of the joint, mechanically minced and then glued onto a synthetic, absorbable scaffold before transplantation into the cartilage defect. In a prospective clinical safety study, this novel autologous scaffold-based allograft procedure was compared with microfracture; clinical and imaging results showed the scaffold-based approach resulted in better functional outcomes, better cartilage development and fewer adverse events.<sup>88</sup> A larger prospective controlled study investigating the mechanical integrity of neotissue formed with this technique, by quantitative MRI techniques and second-look arthroscopy, was stopped by the sponsor due to the difficulty in adhering to strict FDA inclusion criteria.<sup>113</sup> Future studies should correlate structural changes (as measured by quantitative MRI techniques or established morphological methods) with either clinician-based evaluation scales or patient-reported outcome assessment tools.

### Novel cell-free biomaterials

Although autologous chondrocytes and MSC-based techniques offer much promise for articular cartilage repair, methods for extracting, proliferating and differentiating cells are both timely and costly. Furthermore, because MACI-based and hyaluronic-acid-scaffold-based techniques are cellular, the FDA might consider them both as a medical device and as biological, resulting in long and expensive regulatory approval. These regulatory advantages thereby enhance interest in these cell-free material-based products for cartilage regeneration and repair.

**AMIC**—Autologous matrix-induced chondrogenesis (AMIC) is a cell-free technique that can be performed in a single surgery (Figure 3). To perform AMIC, a mini-arthrotomy exposes and cleans the defect site, then microfracture releases both blood and bone marrow containing MSCs, and finally a mixed collagen type I and type III matrix is sutured or glued into the cartilage defect.<sup>89</sup> The implanted collagen matrix is thought to stabilize the resulting blood clot, helping to promote early mechanical stability and cartilage regeneration. Case series have found AMIC to be both safe and effective in treating full-thickness cartilage defects.<sup>90–93</sup> In one study, patients followed-up for as long as 5 years had substantial improvements in Tegner, Lysholm, ICRS, and Cincinatti scores (Box 1) as early as 12

months after surgery.<sup>92</sup> Furthermore, MRI revealed moderate-to-complete filling of all chondral defects. In another AMIC study, a biphasic osteochondral biodegradable scaffold consisting of calcium triphosphate in the osseous region and poly(lactic-co-glucolic acid) in the cartilaginous region was used to treat full-thickness ankle cartilage defects.<sup>93</sup> At a 1 year follow-up, American Orthopaedic Foot & Ankle Society and Ankle Osteoarthritis Scale clinical scores (Box 1) were increased in all six patients compared with preoperative values. Interestingly, the observed clinical outcomes in AMIC-treated patients did not correlate with age, BMI or the number of previous orthopaedic operations of these patients. The small number of cases in these studies, the short follow-up and not having control groups might explain the lack of such correlations. The simplicity and cost-effectiveness of AMIC merits further studies to identify the quality of neocartilage formation, the reproducibility of the data and any potential pitfalls associated with the technique.

**Active in situ approaches**—A novel approach to enhance cartilage repair with AMIC is to deliver growth factors that selectively recruit and stimulate MSCs from the subchondral bone marrow into cell-free scaffolds. Such growth factors can be tailored to also activate chondrocytes in the surrounding healthy tissue to help remodel the repair tissue filling the cartilage defect.

Implanting polymer-based materials combined with autologous serum or platelet-rich plasma and hyaluronic acid after initial microfracture of a defect has been proposed as a novel strategy for active *in situ* AMIC.<sup>94</sup> Autologous serum and platelet-rich plasma can recruit bone marrow MSCs from the underlying subchondral bone,<sup>95</sup> and hyaluronic acid might help the bone marrow MSCs differentiate into a chondrocytic phenotype.<sup>114</sup> A clinical trial found 52 patients receiving this treatment had improved patient-reported Knee injury and Osteoarthritis Outcome Scores (KOOS) 1 year after surgery, compared with their preoperative status (Box 1), and defects were shown, by histological analysis, to be filled with a hyaline-like repair tissue.<sup>96</sup> However, controlled trials with a longer follow-up period are needed to confirm these data and prove that the neotissue is durable. In another method, chitosan in a glycerol phosphate buffer is mixed with freshly drawn autologous whole blood to form a clot.<sup>97</sup> A multicentre, randomized comparative clinical trial found that 1 year after operation a combined treatment of chitosan–glycerol phosphate and microfracture resulted in greater lesion filling and a superior quality of repair tissue than microfracture alone.<sup>98</sup> However, no significant differences in the functional outcomes were detected between the groups at follow-up. Given that fibrocartilage formed after microfracture starts to deteriorate as soon as 2 years after surgery,<sup>4</sup> longer follow-up studies of the functional outcomes are needed to investigate the potential benefits of these active *in situ* AMIC techniques.

Knowledge of the dose dependence and tissue specificity of MSC chemoattractants, including bone morphogenetic proteins, whole blood serum, chemokines and platelet-rich plasma could be used as part of an active *in situ* AMIC cartilage repair strategy.<sup>99,100</sup> Potentially, these treatments could be tailored for a specific condition and anatomical location. Although most of these treatments are FDA-approved and are immediately available for clinical application, well-designed preclinical studies followed by controlled clinical trials are first needed to investigate their effectiveness. Additionally, growth factors belonging to the TGF- $\beta$  superfamily, as well as insulin-like growth factors, platelet-derived

growth factors and pro-epidermal growth factor, have been shown to enhance stem cell chemotactic migration.<sup>101</sup> Methods could therefore be developed to combine both growth factors and MSC chemoattractants to further promote cartilage regeneration by tailoring their release in a controlled manner, for example on the surface of matrices or within nanoparticles.<sup>102</sup>

### Scaffold-free approaches

**Self-assembling process**—Although several tissue engineering approaches for cartilage repair forgo the use of either cells or exogenous stimulation, another option is a self-assembling process that requires no scaffold (Figure 3).<sup>103</sup> Without a scaffold to interrupt cell–cell signalling and stress shielding, the neotissue microenvironment might be more bioactive, enhancing the response to stimulation and integration with surrounding tissue (Box 2). *Ex vivo* studies found that stimulation of self-assembled articular cartilage with exogenous (hypoxia, growth factors, crosslinking agents) and biomechanical (hydrostatic pressure) stimulation promotes the development of robust neotissue with similar functional properties as native cartilage.<sup>104–106</sup> These studies also found that scaffold-free neotissue is capable of both integration and *in vivo* maturation.<sup>107</sup> When compared with scaffold-based techniques, the scaffold-free neotissue had superior mechanical properties and a higher percentage of ECM.<sup>108</sup> Thus, scaffold-free neotissue is a promising new development in the generation of highly bioactive implants to enhance cartilage repair.

**Chondrospheres**—Another scaffold-free technology for articular cartilage regeneration is based on generating spheroids of autologous chondrocytes (chondrospheres) for implantation (Figure 3). In a minipig cartilage defect model, these spheroids adhered and integrated with full-thickness cartilage defects and produced cartilaginous ECM.<sup>109</sup> The clinical efficacy of chondrospheres is currently being investigated in a phase III controlled clinical trial in Europe;<sup>115</sup> the preliminary human clinical outcomes have not yet been published. Another scaffold-free technology is to utilize juvenile allogeneic chondrocytes. These cells have been shown to have a stronger and more stable chondrogenic activity *in vitro* than human adult cells and can avoid immunological responses and form hyaline-like tissue when grafted into goat cartilage defects.<sup>110,111</sup> A phase III clinical trial comparing this technology with microfracture is ongoing; clinical data from this trial are not yet available.

### Conclusions

This Review focuses on the basic science, indications, advantages, limitations and outcomes of current and future cartilage regeneration strategies. Emphasis is on tissue engineering approaches because such techniques are the basis for the next generation of cartilage regeneration technology. Specifically, tissue engineering aims to develop biomimetic tissues that recapitulate the biological, structural and functional features of native cartilage, increasing the ability of implants to withstand and adapt to the highly loaded environment of the knee. Such strategies are needed, not only stop the progression of cartilage degeneration, but also to improve long-term functional outcomes for patients. These novel biomimetic

solutions might help treat an increasing number of individuals with cartilage pathology, as well as limit the economic burden.

Despite the efforts discussed, the generation of truly biomimetic chondral and osteochondral replacements is elusive; however, technological development in many areas is rapid (Figure 4). For example, tissue engineering approaches using a variety of cell sources, including autologous, allogeneic, xenogeneic and stem cells, have yielded repair tissues with hyaline-like characteristics, thereby decreasing pain and in many cases delaying joint degeneration. Although a 'gold standard' cell source has yet to be identified, stem cells stand out in terms of their availability and minimization or lack of donor morbidity. Furthermore, the combination of tissue engineering with both biochemical and biomechanical exogenous stimulation has resulted in repair tissues with even better hyaline-like properties. Tissue-engineered, cell-free scaffolds, as well as cell-based, scaffold-free approaches offer even further hope for the treatment of cartilage repair.

Overall, a technology has yet to be developed that satisfies the fundamental requirements of successful cartilage healing, namely, one that embodies the appropriate structure–function relationship, ECM organization, bioactivity and surgical logistics. To address these criteria, work must be done to improve not only the mechanical properties of the tissue, but also to shape and organize neotissue development so that it better mimics native morphogenesis. Furthermore, emphasis must be placed on the degradation characteristics of scaffold-based approaches to ensure degradation rates match tissue regeneration. In cell-based applications, a thorough understanding of how to maintain the chondrocytic phenotype of autologous and allogeneic chondrocytes, and how to foster complete chondrogenic differentiation of stem cells, must be established. Once technologies are able to pass these criteria, stringent manufacturing methods that ensure reproducibility of the resulting implants and long-term functional clinical outcomes in humans will need to be developed. Standardization of the approval process should also be streamlined across countries; current practices in Europe allow faster translation of promising technologies than the FDA.

Crucial to these endeavours is the development of better animal models of cartilage damage for *in vivo* testing prior to clinical application in well-designed, prospective, randomized controlled clinical trials. Furthermore, such clinical studies should compare novel technologies to current 'gold standard' clinical approaches. The resulting repair tissue must also be subjected to rigorous biochemical and biomechanical evaluation to determine how similar the regenerative tissue is to native tissue. What quantifies a robust, hyaline-like repair tissue, and what threshold of such quantifiable characteristics is necessary for successful clinical outcomes must be clearly determined. Use of noninvasive, quantitative measures both before and after surgery is important to understand long-term clinical trial outcomes. Such information will be critical to determine which technologies result in regenerative tissue that truly recreates the structure–function relationship of healthy, native articular cartilage. Equally important, measures should be taken to determine the appropriate indications, contraindications, patient selection criteria, surgical practices and rehabilitation protocols for each technology. Importantly, the necessity of minimizing health-care costs must also be seriously considered. All-in-all, much work is required to develop truly

biomimetic cartilage regenerative therapies, but we are closer than ever to making such a concept a clinical reality.

## Acknowledgments

The authors acknowledge funding from NIH R01 AR061496, NIH R01 DE019666, NIH R01 DE015038, and California Institute for Regenerative Medicine (CIRM) TR3-05709.

## Biographies

Dr Eleftherios A. Makris gained his medical degree in 2009 from Aristotle University (Medical School), Thessaloniki, Greece. In 2014 he completed his PhD in biomedical engineering, focusing on developing tissue-engineering methods for cartilage regeneration. He has published more than 10 papers focused on cartilage regeneration and tissue engineering. Translating new cartilages technologies to clinical practice is one of his main research interests.

Dr Andreas H. Gomoll received his medical degree from Ludwig-Maximilians Universität in Munich, Germany in 1996, and his PhD in 1997 from Technische Universität, Germany. Currently, Dr Gomoll is on staff at Brigham and Women's Hospital in Boston, USA, and he is Associate Professor of Orthopedic Surgery at Harvard Medical School. He specializes in reconstructive procedures for cartilage defects and early arthritis, such as cartilage and meniscal transplantation, and osteotomy.

Dr Konstantinos N. Malizos gained his medical degree in 1978 from Aristotle University (Medical School), Thessaloniki, Greece. Since 1998 he has served as the Chairman of the Department of Orthopedics and Musculoskeletal Trauma at the Medical School, University of Thessaly, Greece. He has published more than 200 papers in peer-reviewed journals and is International Deputy Editor of the *Journal of Bone & Joint Surgery*.

Dr Jerry C. Hu holds a doctoral degree in Bioengineering from Rice University, USA. He has published more than 40 papers. Since 2000 Dr Hu has focused on the development of cartilage tissue engineering approaches, pioneering the development of the self-assembling process in articular cartilage.

Dr Kyriacos A. Athanasiou holds a doctoral degree in Mechanical (Biomedical) Engineering from Columbia University, USA. He has published approximately 300 papers in peer-reviewed journals and holds 30 patents on numerous FDA-approved medical devices. Since 1989, Dr Athanasiou has focused on cartilage tissue engineering research.

## References

1. Lories RJ, Luyten FP. The bone–cartilage unit in osteoarthritis. *Nat Rev Rheumatol*. 2011; 7:43–49. [PubMed: 21135881]
2. Moran CJ, et al. Restoration of articular cartilage. *J Bone Joint Surg Am*. 2014; 96:336–344. [PubMed: 24553893]
3. Bae DK, Yoon KH, Song SJ. Cartilage healing after microfracture in osteoarthritic knees. *Arthroscopy*. 2006; 22:367–374. [PubMed: 16581448]



4. Kreuz PC, et al. Results after microfracture of full-thickness chondral defects in different compartments in the knee. *Osteoarthritis Cartilage*. 2006; 14:1119–1125. [PubMed: 16815714]
5. Mithoefer K, McAdams T, Williams RJ, Kreuz PC, Mandelbaum BR. Clinical efficacy of the microfracture technique for articular cartilage repair in the knee: an evidence-based systematic analysis. *Am J Sports Med*. 2009; 37:2053–2063. [PubMed: 19251676]
6. Minas T, Gomoll AH, Rosenberger R, Royce RO, Bryant T. Increased failure rate of autologous chondrocyte implantation after previous treatment with marrow stimulation techniques. *Am J Sports Med*. 2009; 37:902–908. [PubMed: 19261905]
7. Pestka JM, Bode G, Salzmann G, Südkamp NP, Niemeier P. Clinical outcome of autologous chondrocyte implantation for failed microfracture treatment of full-thickness cartilage defects of the knee joint. *Am J Sports Med*. 2011
8. Goyal D, et al. Evidence-based status of microfracture technique: a systematic review of level I and II studies. *Arthroscopy*. 2013; 29:1579–1588. [PubMed: 23992991]
9. Gudas R, et al. Comparison of osteochondral autologous transplantation, microfracture, or debridement techniques in articular cartilage lesions associated with anterior cruciate ligament injury: a prospective study with a 3-year follow-up. *Arthroscopy*. 2013; 29:89–97. [PubMed: 23142295]
10. Gomoll AH. Microfracture and augments. *J Knee Surg*. 2012; 25:9–15. [PubMed: 22624242]
11. Saris DB, et al. Treatment of symptomatic cartilage defects of the knee: characterized chondrocyte implantation results in better clinical outcome at 36 months in a randomized trial compared to microfracture. *Am J Sports Med*. 2009; 37(Suppl. 1):10S–19S. [PubMed: 19846694]
12. Saris DB, et al. Characterized chondrocyte implantation results in better structural repair when treating symptomatic cartilage defects of the knee in a randomized controlled trial versus microfracture. *Am J Sports Med*. 2008; 36:235–246. [PubMed: 18202295]
13. Peterson L, Vasiliadis HS, Brittberg M, Lindahl A. Autologous chondrocyte implantation: a long-term follow-up. *Am J Sports Med*. 2010; 38:1117–1124. [PubMed: 20181804]
14. Minas T, Von Keudell A, Bryant T, Gomoll AH. The John Insall Award: a minimum 10-year outcome study of autologous chondrocyte implantation. *Clin Orthop Relat Res*. 2014; 472:41–51. [PubMed: 23979923]
15. Behery OA, Harris JD, Karnes JM, Siston RA, Flanigan DC. Factors influencing the outcome of autologous chondrocyte implantation: a systematic review. *J Knee Surg*. 2013; 26:203–11. [PubMed: 23288737]
16. Filardo G, Kon E, Di Martino A, Iacono F, Marcacci M. Arthroscopic second-generation autologous chondrocyte implantation: a prospective 7-year follow-up study. *Am J Sports Med*. 2011; 39:2153–2160. [PubMed: 21803978]
17. Macmull S, et al. Autologous chondrocyte implantation in the adolescent knee. *Am J Sports Med*. 2011; 39:1723–1730. [PubMed: 21531864]
18. Trinh TQ, Harris JD, Siston RA, Flanigan DC. Improved outcomes with combined autologous chondrocyte implantation and patellofemoral osteotomy versus isolated autologous chondrocyte implantation. *Arthroscopy*. 2013; 29:566–574. [PubMed: 23312875]
19. Bentley G, et al. Minimum ten-year results of a prospective randomised study of autologous chondrocyte implantation versus mosaicplasty for symptomatic articular cartilage lesions of the knee. *J Bone Joint Surg Br*. 2012; 94:504–509. [PubMed: 22434467]
20. Basad E, Ishaque B, Bachmann G, Stürz H, Steinmeyer J. Matrix-induced autologous chondrocyte implantation versus microfracture in the treatment of cartilage defects of the knee: a 2-year randomised study. *Knee Surg Sports Traumatol Arthrosc*. 2010; 18:519–527. [PubMed: 20062969]
21. Saris D, et al. Matrix-applied characterized autologous cultured chondrocytes versus microfracture: two-year follow-up of a prospective randomized trial. *Am J Sports Med*. 2014
22. Van Assche D, et al. Autologous chondrocyte implantation versus microfracture for knee cartilage injury: a prospective randomized trial, with 2-year follow-up. *Knee Surg Sports Traumatol Arthrosc*. 2010; 18:486–495. [PubMed: 19820916]

23. Knutsen G, et al. A randomized trial comparing autologous chondrocyte implantation with microfracture. Findings at five years. *J Bone Joint Surg Am.* 2007; 89:2105–2112. [PubMed: 17908884]
24. Peterson L, et al. Two- to 9-year outcome after autologous chondrocyte transplantation of the knee. *Clin Orthop Relat Res.* 2000; 374:212–234. [PubMed: 10818982]
25. Gooding CR, et al. A prospective, randomised study comparing two techniques of autologous chondrocyte implantation for osteochondral defects in the knee: Periosteum covered versus type I/III collagen covered. *Knee.* 2006; 13:203–210. [PubMed: 16644224]
26. Gomoll AH, Probst C, Farr J, Cole BJ, Minas T. Use of a type I/III bilayer collagen membrane decreases reoperation rates for symptomatic hypertrophy after autologous chondrocyte implantation. *Am J Sports Med.* 2009; 37(Suppl. 1):20S–23S. [PubMed: 19841142]
27. Marcacci M, et al. Articular cartilage engineering with Hyalograft C: 3-year clinical results. *Clin Orthop Relat Res.* 2005; 435:96–105. [PubMed: 15930926]
28. Darling EM, Athanasiou KA. Rapid phenotypic changes in passaged articular chondrocyte subpopulations. *J Orthop Res.* 2005; 23:425–432. [PubMed: 15734258]
29. Martinez I, Elvenes J, Olsen R, Bertheussen K, Johansen O. Redifferentiation of *in vitro* expanded adult articular chondrocytes by combining the hanging-drop cultivation method with hypoxic environment. *Cell Transplant.* 2008; 17:987–996. [PubMed: 19069640]
30. Grigolo B, et al. Evidence for redifferentiation of human chondrocytes grown on a hyaluronan-based biomaterial (HYAff 11): molecular, immunohistochemical and ultrastructural analysis. *Biomaterials.* 2002; 23:1187–1195. [PubMed: 11791922]
31. Caron MM, et al. Redifferentiation of dedifferentiated human articular chondrocytes: comparison of 2D and 3D cultures. *Osteoarthritis Cartilage.* 2012; 20:1170–1178. [PubMed: 22796508]
32. Marlovits S, et al. Clinical and radiological outcomes 5 years after matrix-induced autologous chondrocyte implantation in patients with symptomatic, traumatic chondral defects. *Am J Sports Med.* 2012; 40:2273–2280. [PubMed: 22922521]
33. Zheng MH, et al. Matrix-induced autologous chondrocyte implantation (MACI): biological and histological assessment. *Tissue Eng.* 2007; 13:737–746. [PubMed: 17371156]
34. Bartlett W, et al. Autologous chondrocyte implantation versus matrix-induced autologous chondrocyte implantation for osteochondral defects of the knee: a prospective, randomised study. *J Bone Joint Surg Br.* 2005; 87:640–645. [PubMed: 15855365]
35. Zeifang F, et al. Autologous chondrocyte implantation using the original periosteum-cover technique versus matrix-associated autologous chondrocyte implantation: a randomized clinical trial. *Am J Sports Med.* 2010; 38:924–933. [PubMed: 19966102]
36. Bian L, et al. Enhanced MSC chondrogenesis following delivery of TGF- $\beta$ 3 from alginate microspheres within hyaluronic acid hydrogels *in vitro* and *in vivo*. *Biomaterials.* 2011; 32:6425–6434. [PubMed: 21652067]
37. Chung C, Beecham M, Mauck RL, Burdick JA. The influence of degradation characteristics of hyaluronic acid hydrogels on *in vitro* neocartilage formation by mesenchymal stem cells. *Biomaterials.* 2009; 30:4287–4296. [PubMed: 19464053]
38. Kon E, et al. Articular cartilage treatment in high-level male soccer players: a prospective comparative study of arthroscopic second-generation autologous chondrocyte implantation versus microfracture. *Am J Sports Med.* 2011; 39:2549–2557. [PubMed: 21900624]
39. Horák M, et al. Comparison of the cellular composition of two different chondrocyte-seeded biomaterials and the results of their transplantation in humans. *Folia Biol (Praha).* 2014; 60:1–9. [PubMed: 24594051]
40. Tatsumura M, Sakane M, Ochiai N, Mizuno S. Off-loading of cyclic hydrostatic pressure promotes production of extracellular matrix by chondrocytes. *Cells Tissues Organs.* 2014; 198:405–413. [PubMed: 24777062]
41. Jeon JE, Schrobback K, Hutmacher DW, Klein TJ. Dynamic compression improves biosynthesis of human zonal chondrocytes from osteoarthritis patients. *Osteoarthritis Cartilage.* 2012; 20:906–915. [PubMed: 22548797]
42. Lee CH, et al. Regeneration of the articular surface of the rabbit synovial joint by cell homing: a proof of concept study. *Lancet.* 2010; 376:440–448. [PubMed: 20692530]

43. Khan IM, Gilbert SJ, Singhrao SK, Duance VC, Archer CW. Cartilage integration: evaluation of the reasons for failure of integration during cartilage repair. A review. *Eur Cell Mater.* 2008; 16:26–39. [PubMed: 18770504]
44. Harrington IJ. A bioengineering analysis of force actions at the knee in normal and pathological gait. *Biomed Eng.* 1976; 11:167–172. [PubMed: 1276337]
45. Appelman TP, Mizrahi J, Elisseeff JH, Seliktar D. The influence of biological motifs and dynamic mechanical stimulation in hydrogel scaffold systems on the phenotype of chondrocytes. *Biomaterials.* 2011; 32:1508–1516. [PubMed: 21093907]
46. Ringe J, Burmester GR, Sittinger M. Regenerative medicine in rheumatic disease—progress in tissue engineering. *Nat Rev Rheumatol.* 2012; 8:493–498. [PubMed: 22782007]
47. O’Conor CJ, Leddy HA, Benefield HC, Liedtke WB, Guilak F. TRPV4-mediated mechanotransduction regulates the metabolic response of chondrocytes to dynamic loading. *Proc Natl Acad Sci USA.* 2014; 111:1316–1321. [PubMed: 24474754]
48. Crawford DC, Heveran CM, Cannon WD Jr, Foo LF, Potter HG. An autologous cartilage tissue implant NeoCart for treatment of grade III chondral injury to the distal femur: prospective clinical safety trial at 2 years. *Am J Sports Med.* 2009; 37:1334–1343. [PubMed: 19448048]
49. Crawford DC, DeBerardino TM, Williams RJ 3rd. NeoCart, an autologous cartilage tissue implant, compared with microfracture for treatment of distal femoral cartilage lesions: an FDA phase-II prospective, randomized clinical trial after two years. *J Bone Joint Surg Am.* 2012; 94:979–989. [PubMed: 22637204]
50. de Vries-van Melle ML, et al. Chondrogenic differentiation of human bone marrow-derived mesenchymal stem cells in a simulated osteochondral environment is hydrogel dependent. *Eur Cell Mater.* 2014; 27:112–123. discussion 123. [PubMed: 24488855]
51. Ko JY, Kim KI, Park S, Im GI. *In vitro* chondrogenesis and *in vivo* repair of osteochondral defect with human induced pluripotent stem cells. *Biomaterials.* 2014; 35:3571–3581. [PubMed: 24462354]
52. Wakitani S, et al. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. *Osteoarthritis Cartilage.* 2002; 10:199–206. [PubMed: 11869080]
53. Nejadnik H, Hui JH, Feng Choong EP, Tai BC, Lee EH. Autologous bone marrow-derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study. *Am J Sports Med.* 2010; 38:1110–1116. [PubMed: 20392971]
54. Quarto R, et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. *N Engl J Med.* 2001; 344:385–386. [PubMed: 11195802]
55. Kafienah W, et al. Three-dimensional cartilage tissue engineering using adult stem cells from osteoarthritis patients. *Arthritis Rheum.* 2007; 56:177–187. [PubMed: 17195220]
56. Ringe J, Sittinger M. Tissue engineering in the rheumatic diseases. *Arthritis Res Ther.* 2009; 11:211. [PubMed: 19232063]
57. Krampera M, et al. Role for interferon- $\gamma$  in the immunomodulatory activity of human bone marrow mesenchymal stem cells. *Stem Cells.* 2006; 24:386–398. [PubMed: 16123384]
58. Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. *Annu Rev Pathol.* 2011; 6:457–478. [PubMed: 21073342]
59. Liechty KW, et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after *in utero* transplantation in sheep. *Nat Med.* 2000; 6:1282–1286. [PubMed: 11062543]
60. Wu L, Prins HJ, Helder MN, van Blitterswijk CA, Karperien M. Trophic effects of mesenchymal stem cells in chondrocyte co-cultures are independent of culture conditions and cell sources. *Tissue Eng Part A.* 2012; 18:1542–1551. [PubMed: 22429306]
61. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. *J Cell Physiol.* 2007; 213:341–347. [PubMed: 17620285]
62. Davatchi F, Abdollahi BS, Mohyeddin M, Shahram F, Nikbin B. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. *Int J Rheum Dis.* 2011; 14:211–215. [PubMed: 21518322]

63. Centeno CJ, et al. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. *Pain Physician*. 2008; 11:343–353. [PubMed: 18523506]
64. Emadedin M, et al. Intra-articular injection of autologous mesenchymal stem cells in six patients with knee osteoarthritis. *Arch Iran Med*. 2012; 15:422–428. [PubMed: 22724879]
65. Wong KL, et al. Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: a prospective, randomized controlled clinical trial with 2 years' follow-up. *Arthroscopy*. 2013; 29:2020–2028. [PubMed: 24286801]
66. Kuroda R, et al. Treatment of a full-thickness articular cartilage defect in the femoral condyle of an athlete with autologous bone-marrow stromal cells. *Osteoarthritis Cartilage*. 2007; 15:226–231. [PubMed: 17002893]
67. Wakitani S, et al. Autologous bone marrow stromal cell transplantation for repair of full-thickness articular cartilage defects in human patellae: two case reports. *Cell Transplant*. 2004; 13:595–600. [PubMed: 15565871]
68. Mohal JS, Tailor HD, Khan WS. Sources of adult mesenchymal stem cells and their applicability for musculoskeletal applications. *Curr Stem Cell Res Ther*. 2012; 7:103–109. [PubMed: 22023629]
69. Mehlhorn AT, et al. Differential effects of BMP-2 and TGF- $\beta$ 1 on chondrogenic differentiation of adipose derived stem cells. *Cell Prolif*. 2007; 40:809–823. [PubMed: 18021172]
70. Wang YH, et al. Characterization and evaluation of the differentiation ability of human adipose-derived stem cells growing in scaffold-free suspension culture. *Cytotherapy*. 2014; 16:485–495. [PubMed: 24119649]
71. Manferdini C, et al. Adipose-derived mesenchymal stem cells exert antiinflammatory effects on chondrocytes and synoviocytes from osteoarthritis patients through prostaglandin E2. *Arthritis Rheum*. 2013; 65:1271–1281. [PubMed: 23613363]
72. Parker AM, Katz AJ. Adipose-derived stem cells for the regeneration of damaged tissues. *Expert Opin Biol Ther*. 2006; 6:567–578. [PubMed: 16706604]
73. Koh YG, Choi YJ, Kwon SK, Kim YS, Yeo JE. Clinical results and second-look arthroscopic findings after treatment with adipose-derived stem cells for knee osteoarthritis. *Knee Surg Sports Traumatol Arthrosc*. 2013
74. Fu WL, et al. Repair of large full-thickness cartilage defect by activating endogenous peripheral blood stem cells and autologous periosteum flap transplantation combined with patellofemoral realignment. *Knee*. 2014; 21:609–612. [PubMed: 24405791]
75. Turajane T, et al. Combination of intra-articular autologous activated peripheral blood stem cells with growth factor addition/preservation and hyaluronic acid in conjunction with arthroscopic microdrilling mesenchymal cell stimulation Improves quality of life and regenerates articular cartilage in early osteoarthritic knee disease. *J Med Assoc Thai*. 2013; 96:580–588. [PubMed: 23745314]
76. Saw KY, et al. Articular cartilage regeneration with autologous peripheral blood progenitor cells and hyaluronic acid after arthroscopic subchondral drilling: a report of 5 cases with histology. *Arthroscopy*. 2011; 27:493–506. [PubMed: 21334844]
77. Saw KY, et al. Articular cartilage regeneration with autologous peripheral blood stem cells versus hyaluronic acid: a randomized controlled trial. *Arthroscopy*. 2013; 29:684–694. [PubMed: 23380230]
78. Mendelson A, et al. Chondrogenesis by chemotactic homing of synovium, bone marrow, and adipose stem cells *in vitro*. *FASEB J*. 2011; 25:3496–3504. [PubMed: 21746864]
79. Sakaguchi Y, Sekiya I, Yagishita K, Muneta T. Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. *Arthritis Rheum*. 2005; 52:2521–2529. [PubMed: 16052568]
80. Shao, Z., et al. Surface modification on polycaprolactone electrospun mesh and human decalcified bone scaffold with synovium-derived mesenchymal stem cells-affinity peptide for tissue engineering. *J Biomed Mater Res A*. <http://dx.doi.org/doi:10.1002/jbm.a.35177>
81. Sanchez-Adams J, Athanasiou KA. Dermis isolated adult stem cells for cartilage tissue engineering. *Biomaterials*. 2012; 33:109–119. [PubMed: 21959004]

82. Diekman BO, et al. Cartilage tissue engineering using differentiated and purified induced pluripotent stem cells. *Proc Natl Acad Sci USA*. 2012; 109:19172–19177. [PubMed: 23115336]
83. Park, S.; Im, GI. Embryonic stem cells and induced pluripotent stem cells for skeletal regeneration. *Tissue Eng Part B Rev*. <http://dx.doi.org/10.1089/ten.teb.2013.0530>
84. Kim MJ, et al. Generation of human induced pluripotent stem cells from osteoarthritis patient-derived synovial cells. *Arthritis Rheum*. 2011; 63:3010–3021. [PubMed: 21953087]
85. Gross AE, et al. Fresh osteochondral allografts for posttraumatic knee defects: long-term followup. *Clin Orthop Relat Res*. 2008; 466:1863–1870. [PubMed: 18465182]
86. Bonner KF, Daner W, Yao JQ. 2-year postoperative evaluation of a patient with a symptomatic full-thickness patellar cartilage defect repaired with particulated juvenile cartilage tissue. *J Knee Surg*. 2010; 23:109–114. [PubMed: 21141688]
87. Farr J, Cole BJ, Sherman S, Karas V. Particulated articular cartilage: CAIS and DeNovo NT. *J Knee Surg*. 2012; 25:23–29. [PubMed: 22624244]
88. Cole BJ, et al. Outcomes after a single-stage procedure for cell-based cartilage repair: a prospective clinical safety trial with 2-year follow-up. *Am J Sports Med*. 2011; 39:1170–1179. [PubMed: 21460066]
89. Benthien JP, Behrens P. The treatment of chondral and osteochondral defects of the knee with autologous matrix-induced chondrogenesis (AMIC): method description and recent developments. *Knee Surg Sports Traumatol Arthrosc*. 2011; 19:1316–1319. [PubMed: 21234543]
90. Kusano T, et al. Treatment of isolated chondral and osteochondral defects in the knee by autologous matrix-induced chondrogenesis (AMIC). *Knee Surg Sports Traumatol Arthrosc*. 2012; 20:2109–2115. [PubMed: 22198419]
91. Gille J, et al. Outcome of Autologous Matrix Induced Chondrogenesis (AMIC) in cartilage knee surgery: data of the AMIC Registry. *Arch Orthop Trauma Surg*. 2013; 133:87–93. [PubMed: 23070222]
92. Gille J, et al. Mid-term results of Autologous Matrix-Induced Chondrogenesis for treatment of focal cartilage defects in the knee. *Knee Surg Sports Traumatol Arthrosc*. 2010; 18:1456–1464. [PubMed: 20127072]
93. Pearce CJ, Gartner LE, Mitchell A, Calder JD. Synthetic osteochondral grafting of ankle osteochondral lesions. *Foot Ankle Surg*. 2012; 18:114–118. [PubMed: 22443998]
94. Patrascu JM, Freymann U, Kaps C, Poenaru DV. Repair of a post-traumatic cartilage defect with a cell-free polymer-based cartilage implant: a follow-up at two years by MRI and histological review. *J Bone Joint Surg Br*. 2010; 92:1160–1163. [PubMed: 20675765]
95. Patel S, Dhillon MS, Aggarwal S, Marwaha N, Jain A. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. *Am J Sports Med*. 2013; 41:356–364. [PubMed: 23299850]
96. Siclari A, Mascaro G, Gentili C, Cancedda R, Boux E. A cell-free scaffold-based cartilage repair provides improved function hyaline-like repair at one year. *Clin Orthop Relat Res*. 2012; 470:910–919. [PubMed: 21965060]
97. Buschmann, MD.; Hoemann, CD.; Hurtig, MB.; Shive, MS. Cartilage Repair Strategies. Williams, R.J., editor. Vol. 1. Humana Press; 2007. p. 85-104.Ch. 7
98. Stanish WD, et al. Novel scaffold-based BST-CarGel treatment results in superior cartilage repair compared with microfracture in a randomized controlled trial. *J Bone Joint Surg Am*. 2013; 95:1640–1650. [PubMed: 24048551]
99. Richter W. Mesenchymal stem cells and cartilage *in situ* regeneration. *J Intern Med*. 2009; 266:390–405. [PubMed: 19765182]
100. Filardo G, et al. Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. *BMC Musculoskelet Disord*. 2012; 13:229. [PubMed: 23176112]
101. Ponte AL, et al. The *in vitro* migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. *Stem Cells*. 2007; 25:1737–1745. [PubMed: 17395768]
102. Lim SM, et al. Dual growth factor-releasing nanoparticle/hydrogel system for cartilage tissue engineering. *J Mater Sci Mater Med*. 2010; 21:2593–2600. [PubMed: 20577785]

103. Huey DJ, Hu JC, Athanasiou KA. Unlike bone, cartilage regeneration remains elusive. *Science*. 2012; 338:917–921. [PubMed: 23161992]
104. Makris EA, Hu JC, Athanasiou KA. Hypoxia-induced collagen crosslinking as a mechanism for enhancing mechanical properties of engineered articular cartilage. *Osteoarthritis Cartilage*. 2013; 21:634–641. [PubMed: 23353112]
105. Makris EA, MacBarb RF, Responde DJ, Hu JC, Athanasiou KA. A copper sulfate and hydroxylysine treatment regimen for enhancing collagen cross-linking and biomechanical properties in engineered neocartilage. *FASEB J*. 2013; 27:2421–2430. [PubMed: 23457219]
106. Gunja NJ, Uthamanthil RK, Athanasiou KA. Effects of TGF- $\beta$ 1 and hydrostatic pressure on meniscus cell-seeded scaffolds. *Biomaterials*. 2009; 30:565–573. [PubMed: 18980779]
107. Makris EA, MacBarb RF, Paschos NK, Hu JC, Athanasiou KA. Combined use of chondroitinase-ABC, TGF- $\beta$ 1, and collagen crosslinking agent lysyl oxidase to engineer functional neotissues for fibrocartilage repair. *Biomaterials*. 2014; 35:6787–6796. [PubMed: 24840619]
108. Aufderheide AC, Athanasiou KA. Assessment of a bovine co-culture, scaffold-free method for growing meniscus-shaped constructs. *Tissue Eng*. 2007; 13:2195–2205. [PubMed: 17630876]
109. Meyer U, et al. Cartilage defect regeneration by *ex vivo* engineered autologous microtissue—preliminary results. *In Vivo*. 2012; 26:251–257. [PubMed: 22351666]
110. Adkisson HD, et al. The potential of human allogeneic juvenile chondrocytes for restoration of articular cartilage. *Am J Sports Med*. 2010; 38:1324–1333. [PubMed: 20423988]
111. Vanlauwe J, et al. Five-year outcome of characterized chondrocyte implantation versus microfracture for symptomatic cartilage defects of the knee: early treatment matters. *Am J Sports Med*. 2011; 39:2566–2574. [PubMed: 21908720]
112. Cole BJ, Pascual-Garrido C, Grumet RC. Surgical management of articular cartilage defects in the knee. *J Bone Joint Surg Am*. 2009; 91:1778–1790. [PubMed: 19571102]
113. DePuy, Mitek. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2014. Cartilage Autograft Implantation System (CAIS) for the Repair of Knee Cartilage Through Cartilage Regeneration. U.S. National Institutes of Health. Available from: URL of the record NLM Identifier: <http://clinicaltrials.gov/ct2/show/NCT0088102>
114. Patrascu JM, et al. Polyglycolic acid-hyaluronan scaffolds loaded with bone marrow-derived mesenchymal stem cells show chondrogenic differentiation in vitro and cartilage repair in the rabbit model. *J Biomed Mater Res B Appl Biomater*. 2013; 101:1310–20. [PubMed: 23661546]
115. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2014. co.don AG Efficacy and Safety Study of co.Don Chondrosphere to Treat Cartilage Defects U.S. National Institutes of Health. Available from: URL of the record NLM Identifier: <http://clinicaltrials.gov/show/NCT01222559>



### Key points

The limited ability of articular cartilage to regenerate has prompted the development of cell-based tissue engineering techniques, such as autologous chondrocyte implantation

The complexity of autologous chondrocyte implantation and contraindications in wide clinical application have driven the development of matrix-assisted chondrocyte implantation, which uses scaffolds to provide mechanical stability and support chondrogenesis

To improve neotissue formation, graft maturation and biomechanical integrity, cells can be cultured *in vitro* before implantation on 3D matrices with exogenous stimuli, such as growth factors

Biomaterials such as collagen type I and III membranes are also used in cell-free approaches to enhance cartilage's innate regenerative capacity by functioning as scaffolds for resident progenitor cells

Scaffold-free, cell-based techniques to form biomimetic neotissues, which can avoid disadvantages of scaffold use such as limited biocompatibility and release of degradation byproducts, are now in development

Despite promising results and advances in cartilage tissue engineering, translation into clinical practice has not yet been achieved, as many challenges remain to be resolved

**Box 1****Tools to evaluate joint function, cartilage repair and quality of life**

American Orthopaedic Foot & Ankle Society (AOFAS) score: evaluates and monitors the progress of patients after foot and ankle surgery

Cincinnati knee rating scale: evaluates functional status of a degenerative knee based on symptoms, sports activity, daily activities and clinical parameters

EuroQol-visual analogue scale (EQ-VAS): records the patient's self-rated health on a visual analogue scale and records a quantitative measure of health

Foot and Ankle Osteoarthritis Scale (AOS) score: is a visual-analogue, self-administered instrument to measure disability and pain from ankle osteoarthritis

Guillquist knee scoring scale: provides a functional scoring scale for follow-up of knee ligament surgery, concentrating primarily on knee stability

International Cartilage Repair Society (ICRS) score: provides macroscopic evaluation of cartilage repair

International Knee Documentation Committee (IKDC) subjective knee evaluation form: detects improvement or deterioration in function, symptoms and activities due to knee impairment

Knee injury and Osteoarthritis Outcome Score (KOOS): evaluates patients' opinions about their knee and associated problems over short-term and long-term follow up (1 week to decades)

Lysholm knee scoring scale: evaluates outcomes of knee ligament surgery, particularly symptoms of instability

Modified Cincinnati rating system: requires patient input only; provides user with an overall score as well as symptom and functional subscores

Short Form-36 (SF-36): evaluates health status and determines the cost-effectiveness of a treatment in health economics analyses


Tegner activity score: provides a standardized method to evaluate work and sport activities; complements the Lysholm scale, based on observations that limitations in function scores (Lysholm) might be masked by a decrease in activity

Western Ontario and McMaster Universities osteoarthritis index (WOMAC): assesses the course of disease and response to treatment in patients with degenerative hip or knee pathology

**Box 2****Cell response to mechanical load**


Bone and cartilage can adapt to external loads. In bone, this phenomenon is known as Wolff's Law, the theory that if the tissue is exposed to loading, it will remodel to become stronger and better able to withstand the load. Likewise, when load is taken away, the tissue will become weaker, as it is metabolically 'taxing' to maintain a greater tissue mass. Such remodelling occurs at the cellular level via mechanotransductive signalling. A load (or lack of load) will transmit through the matrix of the tissue and convert into a biochemical signal, alerting cells to either produce more ECM or catabolize existing ECM. Cells receive these signals through surface receptors and also alert neighbouring cells. Exogenous materials used in scaffold-based tissue engineering approaches might interrupt the flow of this mechanotransductive signalling cascade, shielding cells from the effects of local stresses and hindering cell-cell signalling. Currently scaffold-free tissue engineering approaches are being developed to help preserve the natural balance between external loading environment and internal tissue architecture.

Abbreviations: ECM, extracellular matrix.




**Figure 1.**

Cartilage regeneration techniques. a | A full-thickness focal chondral lesion. b | The lesion is debrided to ensure healthy, stable margins for integration of the host tissue with the neotissue. c | Microfracture. Channels are created using a 45° awl, spaced 3–4 mm apart, and 3–4 mm deep to penetrate the subchondral bone, allowing MSCs to migrate from the marrow to the cartilage defect. d | ACI. The debrided lesion is filled with 12–48 million autologous chondrocytes and covered with a periosteal flap or mixed collagen type I and type III membrane. e | MACI. The autologous chondrocyte population is expanded *in vitro* and then seeded for 3 days onto an absorbable 3D (collagen types I and III or hyaluronic acid) matrix prior to implantation. The cell-seeded scaffold is then secured into the lesion with fibrin glue. Abbreviations: ACI, autologous chondrocyte implantation; MACI, matrix-assisted autologous chondrocyte implantation; MSCs, mesenchymal stem cells.



**Figure 2.** Algorithm for treatment of cartilage defects. If rehabilitation is not a viable option for a patient with a symptomatic cartilage lesion, the surgeon should assess both the size and location of the defect, determine whether the patient desires a more active (high demand) or sedentary (low demand) lifestyle, and consider if the patient has undergone previous cartilage repair treatments. \*Recommended treatment options for a given situation.<sup>112</sup>



**Figure 3.**

New tissue engineering techniques for treating cartilage lesions. a | Technically mimicking ACI, a debrided chondral lesion is filled with bone-marrow-derived or chondroinduced MSCs, not autologous chondrocytes, and covered with a collagen type I/III membrane. b | Intra-articular injection of MSCs with or without injectable matrices is a single-stage procedure. c | AMIC is a cell-free, scaffold-based single surgery. Microfracture releases blood and bone marrow MSCs, then collagen type I/III, hyaluronic acid or fibrin matrix are sutured or glued into the defect. d | MACI uses scaffolds plus either primary articular chondrocytes or bone-marrow-derived MSCs. e | Neotissue can be formed by combining particulated native cartilage with fibrin glue. Limited autodigestion of ECM releases superficial chondrocytes, which then produce additional ECM that integrates the cartilage particles and fills the defect. f | Scaffold-free techniques include a self-assembling process or chondrospheres. Without a scaffold to interrupt cell-cell signalling and stress shielding, cells are able to respond to stimuli and promote integration of neotissue ECM with the surrounding tissue. Resulting neotissue is thought to be a bioactive microenvironment.




Abbreviations: ACI, autologous chondrocyte implantation; AMIC, autologous matrix-induced chondrogenesis; ECM, extracellular matrix; MACI, matrix-induced autologous chondrocyte implantation; MSCs, mesenchymal stem cells.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Figure 4.**

The tissue engineering paradigm. Cells, signals and scaffolds are the major elements of tissue engineering approaches to cartilage repair. For this purpose, many different cell sources (autologous cells, allogeneic cells or stem cells) have been tested *in vitro*. Neotissue has been cultured *ex vivo* with various stimuli and chemicals to enhance synthesis and chondrogenic potential. To further improve the integrity of neotissues, scaffolds have been used to create a 3D environment to maintain the phenotype of, and carry, integrated cells *in vivo*, and to recruit cells from the host environment. Combinations of these factors drive the three major cartilage engineering strategies that exist: cell-free, scaffold-based implants that

promote cell recruitment with chemoattractants; cell-seeded scaffolds that mimic the structure of native tissues; and scaffold-free, cell-based biomimetic techniques. Abbreviations: AMIC, autologous matrix-induced chondrogenesis; ECM, extracellular matrix; GAG, glycosaminoglycans; MACI, matrix-assisted autologous chondrocyte implantation.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1

Randomized Controlled Trials comparing cartilage regeneration techniques

Study	Treatments	Follow-up (months)	Clinical outcome	
Wong <i>et al.</i> <sup>65</sup> (2013)	Bone marrow MSCs + HA + microfracture ( <i>n</i> = 28) HA + microfracture ( <i>n</i> = 28)	24	The bone marrow MSC-treated group were significantly better in IKDC ( <i>P</i> = 0.001), Lysholm ( <i>P</i> = 0.016), Tegner ( <i>P</i> = 0.021) and MOCART ( <i>P</i> <0.001) scores	Larger mean lesion size in the MSC-recipient group (6.0 cm <sup>2</sup> ) than in the control group (3.5 cm <sup>2</sup> )
Stanish <i>et al.</i> <sup>98</sup> (2013)	BST-CarGel® ( <i>n</i> = 41) Microfracture ( <i>n</i> = 39)	12	MRI showed greater lesion filling ( <i>P</i> = 0.011) and better hyaline cartilage-like MRI T2 values ( <i>P</i> = 0.033) in the BST-CarGel® group than the microfracture group	WOMAC showed equivalent improvement in both groups
Saw <i>et al.</i> <sup>77</sup> (2013)	Subchondral drilling + HA + PBSCs ( <i>n</i> = 25) Subchondral drilling + HA ( <i>n</i> = 25)	18	PBSC group had significantly better ICRS II histological scores ( <i>P</i> = 0.022) and MRI morphological scores ( <i>P</i> = 0.013)	No significant difference in the mean 24-month IKDC scores between the control and intervention groups
Patel <i>et al.</i> <sup>95</sup> (2013)	PRP (1 injection; <i>n</i> = 52) PRP (2 injections; <i>n</i> = 50) Normal saline (1 injection; <i>n</i> = 46)	6	Both PRP-treated groups had better WOMAC questionnaire results ( <i>P</i> <0.001) than the normal saline group; a single dose of PRP is as effective as two PRP injections to alleviate symptoms in OA	The results slightly deteriorated 6 months post surgery in both PRP treated groups
Filardo <i>et al.</i> <sup>100</sup> (2012)	PRP ( <i>n</i> = 54) HA ( <i>n</i> = 55)	12	No significant differences in IKDC, EQ-VAS, Tegner and KOOS scores between the groups	For middle-aged patients with moderate signs of osteoarthritis, PRP was nonsuperior to hyaluronic acid injections
Gudas <i>et al.</i> <sup>9</sup> (2013)	OAT-ACL ( <i>n</i> = 34) Microfracture-ACL ( <i>n</i> = 34) Debridement-ACL ( <i>n</i> = 34) IAC-ACL ( <i>n</i> = 34)	36	The IAC-ACL group's IKDC subjective knee evaluation was significantly better than that of the OAT-ACL group ( <i>P</i> = 0.043) The OAT-ACL group's IKDC subjective knee evaluation was significantly better than that of the microfracture-ACL group ( <i>P</i> = 0.024) and debridement-ACL group ( <i>P</i> = 0.018)	No significant difference between the microfracture-ACL and debridement-ACL group IKDC subjective scores ( <i>P</i> = 0.058)
Crawford <i>et al.</i> <sup>49</sup> (2012)	NeoCart ( <i>n</i> = 21) Microfracture ( <i>n</i> = 9)	24	Improvement in the NeoCart group was significantly better ( <i>P</i> <0.05) than in the microfracture group for KOOS pain, IKDC, KOOS sports, VAS pain and the KOOS quality of life scores	Significantly more NeoCart-treated patients ( <i>P</i> = 0.013) responded to therapy at 6, and 12 months and the trend continued at 24 months
Bentley <i>et al.</i> <sup>19</sup> (2012)	ACI ( <i>n</i> = 58) Mosaicplasty ( <i>n</i> = 42)	120	The functional outcome (Modified Cincinnati knee score and the Stanmore-Bentley functional rating system) was greater for ACI than for mosaicplasty ( <i>P</i> = 0.02)	Repair failed within 10 years of surgery in 10 of 58 (17%) patients in the ACI group and 23 of 42 (55%) in the mosaicplasty group ( <i>P</i> <0.001)
Vanlauwe <i>et al.</i> <sup>111</sup> (2011)	CCI ( <i>n</i> = 51) Microfracture ( <i>n</i> = 61)	60	CCI and microfracture were comparable for the KOOS and oKOOS scores; in the early treatment group CCI was statistically significant ( <i>P</i> = 0.026) and clinically better than microfracture	Treatment failures were comparable ( <i>n</i> = 7 in CCI vs <i>n</i> = 10 in microfracture), although microfracture failures tended to occur earlier
Cole <i>et al.</i> <sup>88</sup> (2011)	CAIS ( <i>n</i> = 20) Microfracture ( <i>n</i> = 9)	24	No differences in the number of adverse events (SF-36) between CAIS and microfracture groups The IKDC and KOOS scores of the CAIS groups were significantly ( <i>P</i> <0.05) higher than the microfracture group	Differences between the 2 groups in fill of the graft bed, tissue integration, or presence of subchondral cysts were not detected by imaging analysis

Study	Treatments	Follow-up (months)	Clinical outcome	
Basad <i>et al.</i> <sup>20</sup> (2010)	MACI ( <i>n</i> = 40) Microfracture ( <i>n</i> = 20)	24	MACI was significantly more effective than microfracture according to the Lysholm ( <i>P</i> = 0.005), Tegner ( <i>P</i> = 0.04), ICRS patient ( <i>P</i> = 0.03), and ICRS surgeon ( <i>P</i> = 0.02) scores	MACI was superior to microfracture in the treatment of large (>4 cm <sup>2</sup> ), symptomatic articular defects
Zeifang <i>et al.</i> <sup>35</sup> (2010)	MACI ( <i>n</i> = 11) ACI ( <i>n</i> = 10)	24	No differences in the IKDC ( <i>P</i> = 0.4994), Tegner Activity ( <i>P</i> = 0.1043) scores and SF-36 ( <i>P</i> = 0.4063) of ACI and MACI techniques. Lysholm and Gillquist scores at 12 months ( <i>P</i> = 0.0449) and 24 months ( <i>P</i> = 0.0487) favoured ACI	MOCART revealed no significant difference between the 2 groups ( <i>P</i> = 0.692)
Van Assche <i>et al.</i> <sup>22</sup> (2010)	ACI ( <i>n</i> = 34) Microfracture ( <i>n</i> = 33)	24	ACI had similar overall functional outcomes to microfracture	ACI resulted in slower recovery at 9 and 12 months compared with microfracture

Abbreviations: ACI, autologous chondrocyte implantation; ACL, anterior cruciate ligament; CAIS, cartilage autograft implantation system; CCI, characterized chondrocyte implantation; EQ-VAS, EuroQol-visual analog scale; HA, hyaluronic acid; IAC, intact articular cartilage; ICRS, International Cartilage Repair Society; IKDC, international knee documentation committee; KOOS, knee injury and osteoarthritis outcome score; MACI, matrix-assisted chondrocyte implantation; MSCs, mesenchymal stem cells; OA, osteoarthritis; OAT, osteochondral autologous transplantation; oKOOS, overall knee injury and osteoarthritis outcome score; PBSC, peripheral blood stem cell; PRP, platelet-rich plasma; SF-36, short form-36; WOMAC, Western Ontario and McMaster osteoarthritis index.